Navigation Links
Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide investigator from Kings College, London. Dr. Macdougall's poster included data in previously-treated dialysis patients and treatment naive, non-dialysis patients which demonstrated that mean hemoglobin (Hgb) levels could be maintained and corrected, respectively, with once monthly Hematide.

Specifically, the data showed that in non-dialysis patients an initial range of doses from .025 mg/kg to .075 mg/kg of Hematide, in conjunction with dose adjustments, is adequate to increase Hgb in anemic patients with renal failure when administered monthly. In addition, intravenous and subcutaneous dosing appeared to result in a similar Hgb increase.

"These data support further investigation of the versatility and flexibility of once-per-month Hematide in terms of starting doses and route of administration," said Robert Naso, Ph.D., executive vice president of Research and Development at Affymax. "These results demonstrate that a narrow target range of hemoglobin levels can be reached with different initial Hematide doses. We are pleased to have such thorough evaluation of the product as we prepare for pivotal Phase 3 clinical trials."

At the time of the presentation, the data generated to date were from two multi-center, open-label studies that have enrolled a total of 304 patients. Safety data were based on the entire patient population, while pharmacodynamic data were based on 179 patients who had mostly completed six months of treatment at European and U.S. clinical sites. Of those, 89 treatment-naive CKD patients who were not on dialysis in the correction study were treated with Hematide once every four weeks. The me an Hgb level was 10.2 g/dL at study entry and was increased to greater than 11 g/dL following an initial dose of Hematide. In the maintenance-conversion study, 90 patients previously treated with Epoetin alfa were switched to Hematide once every four weeks. The mean baseline Hgb level, which was 11.5 g/dL at baseline, was maintained within +/- 1.0 g/dL at the end of six months of treatment. Hematide was generally well tolerated and compatible with adverse events usually observed in patients with chronic kidney disease, with 6 percent of patients reporting adverse events possibly related to Hematide such as fatigue, rash and hypertension and 0.7 percent of patients reporting serious adverse events possibly related to Hematide (one transient ischemic attack in a patient with history of atrial fibrillation, and one moderate infusion reaction in a patient who responded to outpatient intervention).

About Hematide

Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in patients with chronic renal failure and cancer patients receiving chemotherapy.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic renal failure and cancer. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program, the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, the potential for once per month dosing, regulatory requirements and approvals, research and development efforts, industry and competitive environment, intellectual property rights and disputes and other matters that are described in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release.

Contact

Affymax, Inc.
Sylvia Wheeler, 650-812-8861
Executive Director, Corporate Communications


'"/>




Related medicine technology :

1. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
2. Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Global Cervical Dysplasia Market: ... global cervical dysplasia market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/7/2016)...  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: PTN) ... disclosed underwritten public offering of units with gross ... book-running manager, Roth Capital Partners acted as lead ... for the offering. "This financing provides ... allowing us to continue advancing bremelanotide for hypoactive ...
(Date:12/7/2016)... , Dec. 7, 2016 ... on pulmonary drugs studies the current as well ... stakeholders of this report include companies and intermediaries ... pulmonary/respiratory drugs and/or drug-device combinations as well as ... report comprises an elaborate executive summary along with ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... Levels of a protein in the blood associated with heart disease ... the journal Radiology. , Heart disease and brain disease exact a major burden on ... population. Damage to both organs often occurs at a subclinical stage, or before signs ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... 2016 , ... The Honolulu cosmetic and medical dermatology practice ... October 17, 2016, features comprehensive information regarding a wide range of dermatologic conditions, ... can discover the latest clinical dermatology treatments for medical skin concerns as well ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live From ... Folio: Marketing Awards competition. Live From won in the Use of Social Media ... ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
Breaking Medicine News(10 mins):